Edgewise Therapeutics, Inc. (EWTX) News
Track canonical SquawkNews coverage tagged to EWTX, Edgewise Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 4 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36
Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ: EWTX ) with a Neutral and raises the price target from $32 to $36.
EQUITY | Aug 11, 2026, 05:52 PM UTC
L
EWTX EWTX - Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
EWTX EWTX - Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 06, 2026, 12:01 PM UTC
L
Edgewise Therapeutics' EDG-7500 Seen Entering 'Catalyst-Dense' Regulatory Period, Oppenheimer Says
() -- Edgewise Therapeutics (EWTX) is entering a "catalyst-dense" period for EDG-7500, highlighted by an end-of-phase 2 FDA meeting in H2 and the planned start of a phase 3 study in Q4, Oppenheimer said in a Thursday not
REGULATION | Jul 09, 2026, 03:17 PM UTC
L
Buy Recommendation Issued On EWTX By Guggenheim
2026-07-06 09:15:08 ET Guggenheim analyst issues BUY recommendation for EWTX on July 6, 2026 12:17PM ET. <
EQUITY | Jul 06, 2026, 01:15 PM UTC